Profile data is unavailable for this security.
About the company
Syngene International Limited is an India-based integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The Company's services include discovery, development, manufacturing, SynVent Integrated Drug discovery, dedicated centers, and Center for Advanced Protein Studies (CAPS). Its discovery services span the entire spectrum of early-stage research from target identification to delivery of drug candidates for further development. It offers preclinical development, active pharmaceutical ingredient and drug product development for both small molecules and biologics. It has capabilities for current Good Manufacturing Practices (cGMP) manufacturing from benchtop volume to commercial scale. SynVent is its drug discovery platform for enabling fully integrated therapeutic drug discovery and development across small molecules, new modalities and biologics.
- Revenue in INR (TTM)37.20bn
- Net income in INR3.52bn
- Incorporated1993
- Employees6.53k
- LocationSyngene International LtdSyngene International Ltd, Biocon Park, SEZ,, Bommasandra IndustrBANGALORE 560 099IndiaIND
- Phone+91 8 068918000
- Fax+91 8 068918808
- Websitehttps://www.syngeneintl.com/
More ▼
Mergers & acquisitions
| Acquired company | SYNGENE:NSI since announced | Transaction value |
|---|---|---|
| Emergent BioSolutions Inc-Drug Substance Manufacturing Facility | -36.58% | 36.50m |
Data delayed at least 15 minutes, as of Feb 18 2026 10:29 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bio-Thera Solutions Ltd | 11.09bn | -4.84bn | 128.74bn | 1.17k | -- | 20.27 | -- | 11.61 | -0.8908 | -0.8908 | 2.04 | 1.17 | 0.3702 | 0.7722 | 5.96 | -- | -16.15 | -16.38 | -33.76 | -22.22 | 74.99 | 77.05 | -43.63 | -62.11 | 0.4617 | -34.12 | 0.573 | -- | 5.44 | 302.90 | -29.34 | -- | 11.14 | -- |
| Rubicon Research Ltd | 15.98bn | 2.06bn | 129.91bn | 1.14k | 60.34 | -- | 52.98 | 8.13 | 13.07 | 13.07 | 102.06 | -- | -- | -- | -- | 14,424,080.00 | -- | -- | -- | -- | 68.82 | -- | 12.90 | -- | -- | 12.92 | -- | -- | 50.40 | -- | 47.63 | -- | -- | -- |
| Suzhou Ribo Life Science Co Ltd | 2.36bn | -2.90bn | 140.62bn | 404.00 | -- | -- | -- | 59.51 | -1.54 | -1.54 | 1.26 | -0.4088 | -- | -- | -- | -- | -- | -- | -- | -- | 90.90 | -- | -131.95 | -- | 0.9173 | -14.93 | 0.8949 | -- | 324,052.30 | -- | 36.93 | -- | -- | -- |
| Onesource Specialty Pharma Ltd | 14.19bn | 207.92m | 148.46bn | 1.41k | 712.29 | -- | 50.06 | 10.46 | 1.82 | 1.76 | 129.84 | -- | -- | -- | -- | 10,051,880.00 | -- | -- | -- | -- | 70.99 | -- | 1.46 | -- | -- | 0.8886 | -- | -- | 740.43 | -- | 95.27 | -- | -- | -- |
| Nanjing Leads Biolabs Co Ltd | 0.00 | -3.77bn | 151.07bn | 192.00 | -- | 104.10 | -- | -- | -2.00 | -2.00 | 0.00 | 0.6292 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.01 | -- | 0.7407 | -- | -100.00 | -- | 16.85 | -- | -- | -- |
| HitGen Inc | 6.54bn | 1.50bn | 154.80bn | 483.00 | 104.30 | 8.02 | -- | 23.67 | 0.2824 | 0.2824 | 1.24 | 3.67 | 0.2726 | 6.37 | 4.69 | 1,032,114.00 | 6.18 | 3.06 | 6.87 | 3.36 | 55.23 | 53.55 | 22.67 | 14.48 | 5.12 | 6.59 | 0.1674 | 34.32 | 14.99 | 10.08 | 26.13 | -15.65 | 3.16 | -- |
| InventisBio Co Ltd | 2.37bn | -1.53bn | 166.99bn | 185.00 | -- | 7.64 | -- | 70.51 | -0.2012 | -0.2012 | 0.3122 | 2.88 | 0.0988 | -- | 1.03 | 975,824.70 | -6.36 | -32.89 | -6.76 | -35.22 | 99.41 | -- | -64.41 | -682.73 | -- | -- | 0.0127 | -- | -9.02 | 25.00 | 15.41 | -- | -3.97 | -- |
| Syngene International Ltd | 37.20bn | 3.52bn | 173.92bn | 6.53k | 49.62 | -- | 21.94 | 4.67 | 8.72 | 8.72 | 92.16 | -- | -- | -- | -- | 5,694,474.00 | -- | 8.14 | -- | 10.44 | 75.26 | 71.29 | 9.46 | 15.03 | -- | 5.73 | -- | -- | 4.41 | 12.60 | -2.71 | 3.78 | 3.67 | -- |
| Keymed Biosciences Inc | 11.44bn | -3.38bn | 187.07bn | 1.47k | -- | 4.46 | -- | 16.35 | -1.11 | -1.11 | 3.75 | 12.10 | 0.2068 | 0.3382 | 15.10 | 784,338.50 | -6.10 | -40.63 | -7.27 | -44.60 | 95.19 | -- | -29.48 | -593.20 | 3.74 | -- | 0.2145 | -- | 20.91 | -- | -43.38 | -- | 28.05 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 8.19bn | -12.43bn | 190.92bn | 1.36k | -- | 19.12 | -- | 23.30 | -2.37 | -2.37 | 1.56 | 1.90 | 0.1384 | 0.3458 | 14.57 | 441,048.00 | -21.06 | -29.90 | -36.19 | -36.18 | 88.72 | 85.56 | -152.14 | -1,188.68 | 0.8093 | -10.82 | 0.7353 | -- | 56.28 | 46.68 | 0.9031 | -- | 12.25 | -- |
| Telix Pharmaceuticals Ltd | 60.62bn | 1.01bn | 192.33bn | 234.00 | 207.57 | 5.01 | 89.97 | 3.17 | 0.0426 | 0.0426 | 2.70 | 1.76 | 0.7909 | 11.01 | 7.28 | -- | 1.31 | -10.99 | 1.82 | -15.18 | 54.00 | 61.79 | 1.66 | -13.10 | 1.22 | -- | 0.4978 | -- | 54.81 | 192.25 | 851.60 | -- | 150.32 | -- |
| Mesoblast Ltd | 1.56bn | -9.28bn | 199.71bn | 81.00 | -- | 3.65 | -- | 127.82 | -0.1196 | -0.1196 | 0.0201 | 0.6603 | 0.0237 | -- | 2.25 | 300,355.60 | -14.05 | -13.19 | -15.99 | -14.68 | 70.17 | -132.14 | -593.92 | -957.40 | 1.77 | -4.50 | 0.1766 | -- | 191.39 | -11.76 | -16.13 | -- | -20.16 | -- |
| Ascentage Pharma Group International | 5.12bn | -15.21bn | 202.09bn | 605.00 | -- | 21.62 | -- | 39.44 | -4.02 | -4.02 | 1.35 | 2.16 | 0.1270 | 3.70 | 0.9505 | 779,334.00 | -37.68 | -30.84 | -60.56 | -41.94 | 90.87 | 94.02 | -296.81 | -252.93 | 1.53 | -- | 0.7174 | -- | 341.77 | 132.25 | 56.20 | -- | -21.49 | -- |
Data as of Feb 18 2026. Currency figures normalised to Syngene International Ltd's reporting currency: Indian Rupee INR
28.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 08 May 2025 | 20.40m | 5.06% |
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 19.12m | 4.75% |
| DSP Asset Managers Pvt. Ltd.as of 31 Jan 2026 | 18.71m | 4.64% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Dec 2025 | 15.65m | 3.89% |
| Singapore InvestCorp (India) Pvt Ltd.as of 31 Dec 2025 | 11.69m | 2.90% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 7.47m | 1.85% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 7.32m | 1.82% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Jan 2026 | 6.03m | 1.50% |
| Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Jan 2026 | 4.38m | 1.09% |
| Kotak Mahindra Asset Management (Singapore) Pte Ltd.as of 31 Dec 2024 | 4.08m | 1.01% |
More ▼
Data from 31 Oct 2025 - 10 Feb 2026Source: FactSet Research Systems Inc.
